BRAF V600E assessment by pyrosequencing in fine needle aspirates of thyroid nodules with concurrent Hashimoto's thyroiditis is a reliable assay

Endocrine

Volumn 45, Issue 2, 2014, Pages 249-255

  Guerra, Anna ^a   Di Stasi, Vincenza ^a   Zeppa, Pio ^a   Faggiano, Antongiulio ^b   Marotta, Vincenzo ^b   Vitale, Mario ^a  

^a UNIVERSITY OF SALERNO   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

BRAF mutation; FNAC; Hashimoto's thyroiditis; Papillary thyroid cancer; Pyrosequencing

Indexed keywords

B RAF KINASE; DNA;

ADULT; ALLELE; ARTICLE; BRAF GENE; CONTROLLED STUDY; CYTOLOGY; DIAGNOSTIC VALUE; DNA EXTRACTION; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; GENE MUTATION; HASHIMOTO DISEASE; HUMAN; HUMAN TISSUE; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PYROSEQUENCING; THYROID CARCINOMA; THYROID NODULE;

ADULT; AGED; ALLELES; BIOPSY, FINE-NEEDLE; COMORBIDITY; FEMALE; HASHIMOTO DISEASE; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; REPRODUCIBILITY OF RESULTS; SEQUENCE ANALYSIS, DNA; THYROID GLAND; THYROID NODULE;

EID: 84896695321     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-013-9994-y     Document Type: Article

References (39)

1. D.S. Cooper, G.M. Doherty, B.R. Haugen, R.T. Kloos, S.L. Lee, S.J. Mandel, E.L. Mazzaferri, B. McIver, F. Pacini, M. Schlumberger, S.I. Sherman, D.L. Steward, R.M. Tuttle, Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19(11), 1167-1214 (2009). doi: 10.1089/thy.2009.0110
2. H. Gharib, J.R. Goellner, Fine-needle aspiration biopsy of the thyroid: an appraisal. Ann. Intern. Med. 118(4), 282-289 (1993)
3. Z.W. Baloch, V.A. LiVolsi, Fine-needle aspiration of thyroid nodules: past, present, and future. Endocr. Pract. 10(3), 234-241 (2004)
4. M.R. Sapio, A. Guerra, D. Posca, P.P. Limone, M. Deandrea, M. Motta, G. Troncone, A. Caleo, P. Vallefuoco, G. Rossi, G. Fenzi, M. Vitale, Combined analysis of galectin-3 and BRAFV600E improves the accuracy of fine-needle aspiration biopsy with cytological findings suspicious for papillary thyroid carcinoma. Endocr. Relat. Cancer 14(4), 1089-1097 (2007)
5. Guerra, A., Marotta, V., Deandrea, M., Motta, M., Limone, P.P., Caleo, A., Zeppa, P., Esposito, S., Fulciniti, F., Vitale, M.: BRAF (V600E) associates with cytoplasmatic localization of p27kip1 and higher cytokeratin 19 expression in papillary thyroid carcinoma. Endocrine (2012). doi: 10.1007/s12020-012-9843-4
6. J.E. Barroeta, Z.W. Baloch, P. Lal, T.L. Pasha, P.J. Zhang, V.A. LiVolsi, Diagnostic value of differential expression of CK19, Galectin-3, HBME-1, ERK, RET, and p16 in benign and malignant follicular-derived lesions of the thyroid: an immunohistochemical tissue microarray analysis. Endocr. Pathol. 17(3), 225-234 (2006)
7. M.R. Sapio, D. Posca, A. Raggioli, A. Guerra, V. Marotta, M. Deandrea, M. Motta, P.P. Limone, G. Troncone, A. Caleo, G. Rossi, G. Fenzi, M. Vitale, Detection of RET/PTC, TRK and BRAF mutations in preoperative diagnosis of thyroid nodules with indeterminate cytological findings. Clin. Endocrinol. (Oxf) 66(5), 678-683 (2007)
8. M.R. Sapio, D. Posca, G. Troncone, G. Pettinato, L. Palombini, G. Rossi, G. Fenzi, M. Vitale, Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA). Eur. J. Endocrinol. 154(2), 341-348 (2006)
9. Y.E. Nikiforov, N.P. Ohori, S.P. Hodak, S.E. Carty, S.O. LeBeau, R.L. Ferris, L. Yip, R.R. Seethala, M.E. Tublin, M.T. Stang, C. Coyne, J.T. Johnson, A.F. Stewart, M.N. Nikiforova, Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J. Clin. Endocrinol. Metab. 96(11), 3390-3397 (2011). doi: 10.1210/jc.2011-1469
10. M. Rossi, M. Buratto, S. Bruni, C. Filieri, F. Tagliati, G. Trasforini, R. Rossi, M.D. Beccati, E.C. Degli Uberti, M.C. Zatelli, Role of ultrasonographic/clinical profile, cytology, and BRAF V600E mutation evaluation in thyroid nodule screening for malignancy: a prospective study. J. Clin. Endocrinol. Metab. 97(7), 2354-2361 (2012). doi: 10.1210/jc.2011-3494
11. V. Marotta, A. Guerra, M.R. Sapio, M. Vitale, RET/PTC rearrangement in benign and malignant thyroid diseases: a clinical standpoint. Eur. J. Endocrinol. 165(4), 499-507 (2011). doi: 10.1530/EJE-11-0499
12. C. Nucera, A. Porrello, Z.A. Antonello, M. Mekel, M.A. Nehs, T.J. Giordano, D. Gerald, L.E. Benjamin, C. Priolo, E. Puxeddu, S. Finn, B. Jarzab, R.A. Hodin, A. Pontecorvi, V. Nose, J. Lawler, S. Parangi, B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. Proc Natl Acad Sci USA 107(23), 10649-10654 (2010). doi: 10.1073/pnas.1004934107
13. J.A. Knauf, X. Ma, E.P. Smith, L. Zhang, N. Mitsutake, X.H. Liao, S. Refetoff, Y.E. Nikiforov, J.A. Fagin, Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res. 65(10), 4238-4245 (2005)
14. E.T. Kimura, M.N. Nikiforova, Z. Zhu, J.A. Knauf, Y.E. Nikiforov, J.A. Fagin, High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 63(7), 1454-1457 (2003)
15. M. Xing, BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr. Rev. 28(7), 742-762 (2007). doi: 10.1210/er.2007-0007
16. A. Guerra, M.R. Sapio, V. Marotta, E. Campanile, S. Rossi, I. Forno, L. Fugazzola, A. Budillon, T. Moccia, G. Fenzi, M. Vitale, The primary occurrence of BRAFV600E is a rare clonal event in papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 97(2), 517-524 (2012). doi: 10.1210/jc.2011-0618
17. P. Caturegli, H. Kimura, R. Rocchi, N.R. Rose, Autoimmune thyroid diseases. Curr. Opin. Rheumatol. 19(1), 44-48 (2007). doi: 10.1097/BOR. 0b013e3280113d1a
18. M. Salzano, E. Russo, L. Postiglione, A. Guerra, V. Marotta, S. Esposito, M. Vitale, Interferon-gamma inhibits integrin-mediated adhesion to fibronectin and survival signaling in thyroid cells. J. Endocrinol. 215(3), 439-444 (2012). doi: 10.1530/JOE-12-0335
19. M. Vitale, SEREX: a promising approach for identification of thyroid cancer serological biomarkers. Clin. Endocrinol. (Oxf) 79(1), 12-13 (2013). doi: 10.1111/cen.12161
20. J.H. Lee, Y. Kim, J.W. Choi, Y.S. Kim, The association between papillary thyroid carcinoma and histologically-proven Hashimoto's thyroiditis: a meta-analysis. Eur. J. Endocrinol. 168(3), 343-349 (2013). doi: 10.1530/EJE-12-0903
21. J. Rosai, M.L. Carcangiu, R.A. De Lellis, Tumors of the thyroid gland, in Atlas of Tumor Pathology, Third Series, Fascicle 5, ed. by J.S.L. Rosai (Armed Forces Institute of Pathology, Washington, DC, 1992), pp. 49-62
22. Royal College of Physicians: Fine needle aspiration cytology (FNAC). In: Perros, P. (ed.) Guidelines for the Management of Thyroid Cancer in Adults, pp. 7 - 8. Royal College of Physicians, London (2002)
23. British Thyroid Association, Royal College of Physicians: Fine needle aspiration cytology (FNAC). In: Perros, P. (ed.) Guidelines for the Management of Thyroid Cancer, 2nd edn, pp. 9-10. Royal College of Physicians, London (2007)
24. A. Guerra, L. Fugazzola, V. Marotta, M. Cirillo, S. Rossi, V. Cirello, I. Forno, T. Moccia, A. Budillon, M. Vitale, A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome. J. Clin. Endocrinol. Metab. 97(7), 2333-2340 (2012). doi: 10.1210/jc.2011-3106
25. A. Guerra, M.R. Sapio, V. Marotta, E. Campanile, M.I. Moretti, M. Deandrea, M. Motta, P.P. Limone, G. Fenzi, G. Rossi, M. Vitale, Prevalence of RET/PTC rearrangement in benign and malignant thyroid nodules and its clinical application. Endocr. J. 58(1), 31-38 (2011)
26. M. Xing, A.S. Alzahrani, K.A. Carson, D. Viola, R. Elisei, B. Bendlova, L. Yip, C. Mian, F. Vianello, R.M. Tuttle, E. Robenshtok, J.A. Fagin, E. Puxeddu, L. Fugazzola, A. Czarniecka, B. Jarzab, C.J. O'Neill, M.S. Sywak, A.K. Lam, G. Riesco-Eizaguirre, P. Santisteban, H. Nakayama, R.P. Tufano, S.I. Pai, M.A. Zeiger, W.H. Westra, D.P. Clark, R. Clifton-Bligh, D. Sidransky, P.W. Ladenson, V. Sykorova, Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA 309(14), 1493-1501 (2013). doi: 10.1001/jama.2013.3190
27. M.C. Zatelli, G. Trasforini, S. Leoni, G. Frigato, M. Buratto, F. Tagliati, R. Rossi, L. Cavazzini, E. Roti, E.C. degli Uberti, BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-needle aspiration biopsies. Eur. J. Endocrinol. 161(3), 467-473 (2009). doi: 10.1530/EJE-09-0353
28. N. Kurtulmus, M. Duren, U. Ince, M. Cengiz Yakicier, O. Peker, O. Aydin, E. Altiok, S. Giray, H. Azizlerli, BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness. Endocrine 42(2), 404-410 (2012). doi: 10.1007/s12020-012-9651-x
29. S.K. Kim, T.S. Hwang, Y.B. Yoo, H.S. Han, D.L. Kim, K.H. Song, S.D. Lim, W.S. Kim, N.S. Paik, Surgical results of thyroid nodules according to a management guideline based on the BRAF(V600E) mutation status. J. Clin. Endocrinol. Metab. 96(3), 658-664 (2011). doi: 10.1210/jc.2010-1082
30. E.D. Rossi, M. Martini, S. Capodimonti, P. Straccia, T. Cenci, C.P. Lombardi, A. Pontecorvi, L.M. Larocca, G. Fadda, Diagnostic and prognostic value of immunocytochemistry and BRAF mutation analysis on liquid-based biopsies of thyroid neoplasms suspicious for carcinoma. Eur. J. Endocrinol. 168(6), 853-859 (2013). doi: 10.1530/EJE-13-0023
31. F.C. Schmitt, A. Longatto-Filho, A. Valent, P. Vielh, Molecular techniques in cytopathology practice. J. Clin. Pathol. 61(3), 258-267 (2008). doi: 10.1136/jcp.2006.044347
32. N.P. Ohori, R. Singhal, M.N. Nikiforova, L. Yip, K.E. Schoedel, C. Coyne, K.L. McCoy, S.O. Lebeau, S.P. Hodak, S.E. Carty, Y.E. Nikiforov, BRAF mutation detection in indeterminate thyroid cytology specimens: underlying cytologic, molecular, and pathologic characteristics of papillary thyroid carcinoma. Cancer Cytopathol. 121(4), 197-205 (2013). doi: 10.1002/cncy.21229
33. M. Vitale, Intratumor BRAFV600E heterogeneity and kinase inhibitors in the treatment of thyroid cancer: a call for participation. Thyroid 23(4), 517-519 (2013). doi: 10.1089/thy.2012.0614
34. S.K. Kim, D.L. Kim, H.S. Han, W.S. Kim, S.J. Kim, W.J. Moon, S.Y. Oh, T.S. Hwang, Pyrosequencing analysis for detection of a BRAFV600E mutation in an FNAB specimen of thyroid nodules. Diagn. Mol. Pathol. 17(2), 118-125 (2008). doi: 10.1097/PDM.0b013e31815d059d
35. M.K. Yeo, Z.L. Liang, T. Oh, Y. Moon, S. An, M.K. Kim, K.S. Kim, M. Shong, J.M. Kim, Y.S. Jo, Pyrosequencing cut-off value identifying BRAFV600E mutation in fine needle aspiration samples of thyroid nodules. Clin. Endocrinol. (Oxf) 75(4), 555-560 (2011). doi: 10.1111/j.1365-2265.2011.04115.x
36. R. Gervasi, G. Orlando, M.A. Lerose, B. Amato, G. Docimo, P. Zeppa, A. Puzziello, Thyroid surgery in geriatric patients: a literature review. BMC Surg. 12(Suppl 1), S16 (2012). doi: 10.1186/1471-2482-12-S1-S16
37. P. Zeppa, I. Cozzolino, A.L. Peluso, G. Troncone, A. Lucariello, M. Picardi, C. Carella, F. Pane, A. Vetrani, L. Palombini, Cytologic, flow cytometry, and molecular assessment of lymphoid infiltrate in fine-needle cytology samples of Hashimoto thyroiditis. Cancer 117(3), 174-184 (2009). doi: 10.1002/cncy.20022
38. E. Vigliar, C. Bellevicine, I. Cozzolino, P. Zeppa, Histological and fine needle aspiration cytological features of Hashimoto thyroditis-associated 'angiomatoid' papillary thyroid carcinoma. Cytopathology 23(6), 415-417 (2012). doi: 10.1111/cyt.12014
39. Marotta, V., Guerra, A., Zatelli, M.C., Uberti, E.D., Stasi, V.D., Faggiano, A., Colao, A., Vitale, M.: BRAF mutation positive papillary thyroid carcinoma is less advanced when Hashimoto's thyroiditis lymphocytic infiltration is present. Clin. Endocrinol. (Oxf) (2013). doi: 10.1111/cen.12194